Recently, Tan et al. investigated, in pre-clinical studies, the potential of a therapeutic strategy based on the use of a DNA vaccine expressing soluble PD-1 (sPD-1) linked with TWIST1 construct, with the aim to block the immunotolerance for the self-antigen TWIST1 and destroy cancer cells. This evidence concerns the gene HOXD13 and cancer.